Zupi G - Search Results

1

The future of antisense therapy: combination with anticancer treatments.

Biroccio A, Leonetti C, Zupi G. Biroccio A, et al. Among authors: zupi g. Oncogene. 2003 Sep 29;22(42):6579-88. doi: 10.1038/sj.onc.1206812. Oncogene. 2003. PMID: 14528283 Review.

2

Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones.

Biroccio A, Amodei S, Benassi B, Scarsella M, Cianciulli A, Mottolese M, Del Bufalo D, Leonetti C, Zupi G. Biroccio A, et al. Among authors: zupi g. Oncogene. 2002 May 2;21(19):3011-9. doi: 10.1038/sj.onc.1205415. Oncogene. 2002. PMID: 12082531

3

Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.

Biroccio A, D'Angelo C, Jansen B, Gleave ME, Zupi G. Biroccio A, et al. Among authors: zupi g. J Cell Physiol. 2005 Aug;204(2):463-9. doi: 10.1002/jcp.20295. J Cell Physiol. 2005. PMID: 15685647

4

Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.

Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. Zupi G, et al. Clin Cancer Res. 2005 Mar 1;11(5):1990-8. doi: 10.1158/1078-0432.CCR-04-1284. Clin Cancer Res. 2005. PMID: 15756025

5

Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.

Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G. Leonetti C, et al. Among authors: zupi g. Prostate. 2007 Sep 15;67(13):1475-85. doi: 10.1002/pros.20636. Prostate. 2007. PMID: 17654511

6

Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.

Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M, Del Bufalo D, Zupi G. Leonetti C, et al. Among authors: zupi g. Clin Cancer Res. 1999 Sep;5(9):2588-95. Clin Cancer Res. 1999. PMID: 10499637

7

Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy.

Leonetti C, Zupi G. Leonetti C, et al. Among authors: zupi g. Curr Pharm Des. 2007;13(5):463-70. doi: 10.2174/138161207780162917. Curr Pharm Des. 2007. PMID: 17348843 Review.

8

PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.

Salvati E, Scarsella M, Porru M, Rizzo A, Iachettini S, Tentori L, Graziani G, D'Incalci M, Stevens MF, Orlandi A, Passeri D, Gilson E, Zupi G, Leonetti C, Biroccio A. Salvati E, et al. Among authors: zupi g. Oncogene. 2010 Nov 25;29(47):6280-93. doi: 10.1038/onc.2010.344. Epub 2010 Aug 30. Oncogene. 2010. PMID: 20802516

9

Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity.

Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D. Iervolino A, et al. Among authors: zupi g. FASEB J. 2002 Sep;16(11):1453-5. doi: 10.1096/fj.02-0122fje. Epub 2002 Jul 1. FASEB J. 2002. PMID: 12205045

10

Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy.

Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E, Bove L, Pace A, Stoppacciaro A, Zupi G, Cognetti F, Picardo M. Leonetti C, et al. Among authors: zupi g. Int J Cancer. 2003 Mar 20;104(2):243-50. doi: 10.1002/ijc.10933. Int J Cancer. 2003. PMID: 12569582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters